With this investment, The Vistria Group will support Ora as the globally preferred clinical research partner of ophthalmic innovators. It also marks The Vistria Group’s commitment to further supporting cutting-edge therapies and advancing diversity in specialized clinical research. Ora is the seventh company in The Vistria Group’s pharma services portfolio and underscores the firm’s continued focus on life sciences.
July 19, 2024